Model-based dose selection for phase 3 trials of the selective P2X3 antagonist camlipixant in refractory chronic cough
1. 系统已在2026-04-29 14:00:12对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
N Chauret, M Garin, L Harvey, S Gahir…
B69. Airway Injury …, 2023
atsjournals.org
BELLUS HEALTH-November 2022 Rationale: P2X3 antagonists have shown promise in clinical trials as potential treatment for refractory chronic cough (RCC). The selective P2X3 antagonist camlipixant (BLU-5937) has been studied in refractory chronic cough (RCC) in two phase 2 clinical trials. RELIEF (NCT03979638) was a Phase 2a, 2-period crossover, forced dose-escalation study with camlipixant 25, 50, 100, and 200 mg BID and matching placebo. No clear dose response was observed in RELIEF. SOOTHE (NCT04678206), was …
